Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedNov 03, 2025
DataAggregated Company Financials
Companies9
  • 7D-2.3%
  • 3M4.1%
  • 1Y4.0%
  • YTD9.4%

Over the last 7 days, the Pharma industry has dropped 2.3%, driven by Novartis declining 3.8%. Meanwhile, Galderma Group actually outperformed within the industry, gaining 6.3% in the last week. This takes the industry's 12 month performance to a gain of 4.0%. Looking forward, earnings are forecast to grow by 13% annually.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 03 Nov 2025CHF 476.7bCHF 121.7bCHF 21.6b32.4x22x3.9x
Wed, 01 Oct 2025CHF 475.4bCHF 120.1bCHF 20.9b31.4x22.7x4x
Fri, 29 Aug 2025CHF 481.0bCHF 120.5bCHF 21.0b30.6x22.9x4x
Sun, 27 Jul 2025CHF 460.3bCHF 119.9bCHF 20.7b23.3x22.2x3.8x
Tue, 24 Jun 2025CHF 445.4bCHF 118.3bCHF 19.1b25x23.3x3.8x
Thu, 22 May 2025CHF 440.6bCHF 119.2bCHF 19.3b25.2x22.9x3.7x
Sat, 19 Apr 2025CHF 413.0bCHF 117.3bCHF 18.4b24.6x22.4x3.5x
Mon, 17 Mar 2025CHF 476.6bCHF 121.8bCHF 19.2b29.4x24.9x3.9x
Wed, 12 Feb 2025CHF 476.5bCHF 123.3bCHF 19.3b22.7x24.7x3.9x
Fri, 10 Jan 2025CHF 448.5bCHF 119.8bCHF 21.5b18.7x20.9x3.7x
Sun, 08 Dec 2024CHF 428.1bCHF 117.7bCHF 21.1b18.3x20.3x3.6x
Tue, 05 Nov 2024CHF 451.9bCHF 116.7bCHF 20.9b19.6x21.6x3.9x
Thu, 03 Oct 2024CHF 448.6bCHF 114.6bCHF 19.3b21.4x23.3x3.9x
Sat, 31 Aug 2024CHF 478.3bCHF 114.9bCHF 19.3b22.8x24.8x4.2x
Mon, 29 Jul 2024CHF 463.8bCHF 116.7bCHF 19.7b22.1x23.6x4x
Wed, 26 Jun 2024CHF 437.0bCHF 116.2bCHF 19.7b33.7x22.1x3.8x
Fri, 24 May 2024CHF 413.3bCHF 117.4bCHF 19.9b42.7x20.7x3.5x
Sun, 21 Apr 2024CHF 398.4bCHF 112.4bCHF 19.5b36.9x20.5x3.5x
Tue, 19 Mar 2024CHF 388.1bCHF 111.2bCHF 19.3b37.5x20.1x3.5x
Thu, 15 Feb 2024CHF 378.4bCHF 110.7bCHF 19.7b23.6x19.2x3.4x
Sat, 13 Jan 2024CHF 415.7bCHF 119.4bCHF 18.7b27.1x22.3x3.5x
Mon, 11 Dec 2023CHF 401.6bCHF 121.2bCHF 18.9b24.3x21.3x3.3x
Wed, 08 Nov 2023CHF 385.2bCHF 122.5bCHF 19.1b23.6x20.2x3.1x
Fri, 06 Oct 2023CHF 399.8bCHF 113.6bCHF 18.2b42.6x22x3.5x
Sun, 03 Sep 2023CHF 405.5bCHF 112.1bCHF 18.0b48.3x22.6x3.6x
Tue, 01 Aug 2023CHF 418.1bCHF 114.5bCHF 19.2b48.9x21.7x3.7x
Thu, 29 Jun 2023CHF 415.9bCHF 115.2bCHF 18.9b36.7x22x3.6x
Sat, 27 May 2023CHF 433.0bCHF 115.7bCHF 18.9b39x22.8x3.7x
Mon, 24 Apr 2023CHF 441.0bCHF 114.6bCHF 18.8b42.9x23.5x3.8x
Wed, 22 Mar 2023CHF 398.9bCHF 116.1bCHF 19.0b26.3x21x3.4x
Fri, 17 Feb 2023CHF 402.1bCHF 116.2bCHF 19.0b28.8x21.1x3.5x
Sun, 15 Jan 2023CHF 433.3bCHF 117.2bCHF 34.7b22.4x12.5x3.7x
Tue, 13 Dec 2022CHF 444.5bCHF 117.7bCHF 34.9b23.5x12.7x3.8x
Thu, 10 Nov 2022CHF 461.6bCHF 119.4bCHF 35.6b23.4x13x3.9x
Price to Earnings Ratio

13x


Total Market Cap: CHF 461.6bTotal Earnings: CHF 35.6bTotal Revenue: CHF 119.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 21.3x202320242025
Current Industry PE
  • Investors are relatively neutral on the Swiss Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 21.3x.
  • The industry is trading close to its 3-year average PS ratio of 3.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 15% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market-1.67%
Healthcare-2.05%
Pharma-2.34%
Pharma-2.34%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GALD Galderma GroupCHF 148.506.3%
+CHF 2.1b		81.4%PE115.9x
SDZ Sandoz GroupCHF 53.506.7%
+CHF 1.4b		32.6%PE126.2x
NWRN Newron PharmaceuticalsCHF 14.444.5%
+CHF 12.4m		80.5%PE12.3x
ADXN Addex TherapeuticsCHF 0.065-0.3%
CHF 2.2m		-19.7%PS56.2x

Latest News

NOVN
CHF 99.27
Novartis
7D
-3.8%
1Y
3.9%

NOVN: Future Trial Data And Pipeline Advancements Will Support Steady Returns

Analysts have raised their fair value estimate for Novartis from $98.60 to $102.12. They cite improved revenue growth outlook and stronger profit margins as key drivers of the upward revision.
GALD
CHF 148.50
Galderma Group
7D
6.3%
1Y
81.4%

GALD: Execution On New Aesthetic Launches And Margin Gains Will Sustain Upside

The fair value estimate for Galderma Group has been raised to CHF 149.91 from CHF 142.41. This change reflects analysts' increased confidence due to positive revisions to growth and margin forecasts, as well as a series of upward price target adjustments from major research firms.
ADXN
CHF 0.065
Addex Therapeutics
7D
-0.3%
1Y
-19.7%
ROG
CHF 258.90
Roche Holding
7D
-3.2%
1Y
-4.9%
SDZ
CHF 53.50
Sandoz Group
7D
6.7%
1Y
32.6%

Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach

The analyst consensus price target for Sandoz Group rose modestly, increasing from CHF 50.20 to CHF 50.33. Analysts cited stronger revenue growth and improving profit margins in their updated outlooks.
DESN
CHF 317.00
Dottikon ES Holding
7D
-4.2%
1Y
32.1%

If EPS Growth Is Important To You, Dottikon ES Holding (VTX:DESN) Presents An Opportunity

Oct 10
If EPS Growth Is Important To You, Dottikon ES Holding (VTX:DESN) Presents An Opportunity
NWRN
CHF 14.44
Newron Pharmaceuticals
7D
4.5%
1Y
80.5%
CURN
CHF 12.70
Curatis Holding
7D
-6.3%
1Y
18.7%
COPN
CHF 67.50
Cosmo Pharmaceuticals
7D
-0.6%
1Y
1.0%

Expanding AI Diagnostics And Drug Platforms Will Navigate Regulatory Challenges

Cosmo Pharmaceuticals’ consensus revenue growth forecasts have strengthened and its future P/E valuation has decreased, but despite these more favourable fundamentals, the consensus analyst price target was only marginally reduced from CHF88.37 to CHF87.81. What's in the News Issued FY2025 guidance: total revenues expected between EUR 102 million and EUR 107 million, with recurring revenues of EUR 85 million to EUR 90 million and project-based revenues of EUR 17 million.